Local view for "http://purl.org/linkedpolitics/eu/plenary/2011-02-15-Speech-2-593-375"
Predicate | Value (sorted: default) |
---|---|
rdf:type | |
dcterms:Date | |
dcterms:Is Part Of | |
dcterms:Language | |
lpv:document identification number |
"en.20110215.29.2-593-375"2
|
lpv:hasSubsequent | |
lpv:speaker | |
lpv:spokenAs | |
lpv:translated text |
"The compromise which has been reached is balanced and marks an important advance for patients’ safety and health. I welcome the inclusion of safety devices on the medicines’ packaging. To ensure that these devices are really effective, it is crucial that all those involved in the distribution chain are subject to more stringent rules. The involvement of brokers is undoubtedly a positive step.
The compromise also strikes a balance between protecting patients’ health and the costs which the new regulations will incur for pharmaceutical manufacturers. It is of paramount importance for us to adopt an approach based on the risk of the relevant medicines being falsified. This is why I believe that restricting the new devices to medicines issued on prescription is a welcome measure. It would be inappropriate for pharmaceutical manufacturers who are not targets for falsification to bear the high cost of the security devices.
Finally, the inclusion of online pharmacies marks significant progress for the safety of patients who tend to purchase medicines via the Internet. We cannot allow counterfeiters to benefit from a legal vacuum, thereby endangering patients’ health. Establishing guarantees indicating that a website is selling genuine medicines will assist greatly all those patients who use this purchase method."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples